AWMSG Advice on oral anticoagulation for non-valvular atrial fibrillation
Recommendations for primary care on the role of oral anticoagulant treatment in people with non-valvular atrial fibrillation.
BSR giant cell arteritis guideline
This summary outlines the general principles of identifying and treating patients with giant cell arteritis in primary care and specialist settings. It is recommended that general practitioners refer patients with suspected giant cell arteritis to a clinician with appropriate specialist expertise.
NICE stable angina guideline
A brief summary of NICE's clinical guideline on the management of stable angina. Includes care pathway algorithm, counselling, and secondary prevention.
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
This useful summary covers diagnosis and initial management, outpatient treatment for low-risk pulmonary embolism, anticoagulation treatment for suspected or confirmed deep vein thrombosis or pulmonary embolism, and information and support for people having anticoagulation treatment
Educational resources
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.
Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Please see the bottom of the page for full disclaimer.
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.